Cognitive Function in a Randomized Trial of Evolocumab
Cognitive Function in a Randomized Trial of Evolocumab
About this item
Full title
Author / Creator
Giugliano, Robert P , Mach, François , Zavitz, Kenton , Kurtz, Christopher , Im, Kyungah , Kanevsky, Estella , Schneider, Jingjing , Wang, Huei , Keech, Anthony , Pedersen, Terje R , Sabatine, Marc S , Sever, Peter S , Robinson, Jennifer G , Honarpour, Narimon , Wasserman, Scott M , Ott, Brian R and EBBINGHAUS Investigators
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
To address concerns about cognitive decline with the use of PCSK9 inhibitors, automated neuropsychological testing was performed in patients who received evolocumab or placebo. Evolocumab was noninferior to placebo with respect to cognitive changes from baseline over 19 months.
Alternative Titles
Full title
Cognitive Function in a Randomized Trial of Evolocumab
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_cristin_nora_10852_63031
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_cristin_nora_10852_63031
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1701131
